At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prognostic and Predictive Values of CD155 in Patients With Acute Myeloid Leukemia
In Brief
An observational study evaluating Flow cytometric immunophenotyping, Complete blood count, and 3 other interventions for Neoplasms and 4 related conditions. Completed, enrolled 93 participants across 1 site.
Detailed Summary
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy. It is the most common form of acute leukemia among adults. In the United States, an estimated 19,940 people will be diagnosed with AML in 2020. CD155 expression was associated with an unfavorable prognosis in solid tumors such as colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma, as it correlated with tumor migration, development of metastases, tissue and lymph node invasion, relapse, and poorer survival.
Study Details
Timeline
Interventions
CD155 expression by flow cytometric immunophenotyping
Complete blood count with peripheral blood smear examination
Bone marrow aspiration at both diagnosis and follow up of patients
Karyotyping or AML fluorescence in situ hybridization (FISH) panel for diagnosis and risk stratification of AML patients
Detection of FLT3-ITD mutation in AML patinets